David C. Klonoff, MD, FACP, FRCP Edin, Fellow AIBME, Named American Diabetes Association’s® 2019 Outstanding Physician Clinician in Diabetes
May 15, 2019
The American Diabetes Association® (ADA) will present the 2019 Outstanding Physician Clinician in Diabetes Award to David C. Klonoff, MD, FACP, FRCP Edin, Fellow AIBME. Presented annually, the award honors praiseworthy contributions to diabetes clinical practice. Dr. Klonoff will be recognized with this honor at the National Scientific and Health Care Awards Presentation on Monday, June 10, during the ADA’s 79th Scientific Sessions, June 7-11, 2019, at the Moscone Convention Center in San Francisco.
Dr. Klonoff is Medical Director of the Diabetes Research Institute at Mills-Peninsula Medical Center and a Clinical Professor of Medicine at the University of California, San Francisco. He practices endocrinology in Burlingame, California. In 1998, Dr. Klonoff coined the term “diabetes technology” when the focus of diabetes treatment was on biology. He has been a leader in diabetes hardware, software, digital health and device cybersecurity. In 2000, he founded Diabetes Technology Society, a nonprofit organization that promotes development and use of technology for patients with diabetes.
“Dr. Klonoff’s commitment to advancing the field of diabetes technology has played a key role in improving care and reducing the burden for millions of people with diabetes,” said the ADA’s 2019 President of Health Care and Education Gretchen Youssef, MS, RD, CDE. “Congratulations to Dr. Klonoff for this honor, and we thank him for his continued work to support all who live with and are affected by diabetes.”
Dr. Klonoff has been a Principal Investigator in more than 110 clinical trials of devices and drugs and has published more than 200 articles in PubMed-indexed journals. He is founding editor-in-chief of Journal of Diabetes Science and Technology, and he has chaired three diabetes device cybersecurity standard steering committees including the Diabetes Technology Society Surveillance Program for Cleared Blood Glucose Monitors, the Endocrine Society Continuous Glucose Monitoring (CGM) Clinical Guidelines Committee, and the Clinical & Laboratory Standards Institute (CLSI) CGM Performance Metrics Committee.
The American Diabetes Association’s 79th Scientific Sessions, the world’s largest scientific meeting focused on diabetes research, prevention and care, will be held June 7-11, 2019, at the Moscone Center in San Francisco, California. Nearly 15,000 leading physicians, scientists, health care professionals and industry representatives from around the world are expected to convene at the Scientific Sessions to unveil cutting-edge research, treatment recommendations and advances toward a cure for diabetes. During the five-day meeting, attendees will receive exclusive access to more than 850 presentations and 2,000 original research presentations, participate in provocative and engaging exchanges with leading diabetes experts, and can earn Continuing Medical Education (CME) or Continuing Education (CE) credits for educational sessions. The program is grouped into eight thematic areas: Acute and Chronic Complications; Behavioral Medicine, Clinical Nutrition, Education and Exercise; Clinical Diabetes/Therapeutics; Epidemiology/Genetics; Immunology/Transplantation; Insulin Action/Molecular Metabolism; Integrated Physiology/Obesity; and Islet Biology/Insulin Secretion. Gretchen Youssef, MS, RDN, CDE, President of Health Care and Education, will deliver her address, “It’s All about Access!,” on Saturday, June 8, and Louis H. Philipson, MD, PhD, FACP, President of Medicine and Science, will deliver his lecture, “Precision Medicine—Addressing the Many Faces of Diabetes,” on Sunday, June 9. Join the Scientific Sessions conversation on social media using #ADA2019.
About the American Diabetes Association
Approximately every 21 seconds, someone in the United States is diagnosed with diabetes. Nearly half of the American adult population has diabetes or prediabetes, and more than 30 million adults and children are living with the disease. The American Diabetes Association (ADA) is the nation’s leading voluntary health organization on a mission to prevent and cure diabetes, as well as improve the lives of all people affected by the disease. For nearly 80 years, the ADA has driven discovery by funding research to treat, manage and prevent all types of diabetes, while working relentlessly for a cure. Magnifying the urgency of this epidemic, the ADA works to safeguard policies and programs that protect people with the illness, those at risk of developing diabetes and the health care professionals who serve them by initiating programs, advocacy and education efforts that can lead to improved health outcomes and quality of life. To learn more or to get involved, call 1-800-DIABETES (1-800-342-2383) or visit us at diabetes.org. Information is available in English and Spanish. Join the conversation with us on Facebook (American Diabetes Association), Twitter (@AmDiabetesAssn) and Instagram (@AmDiabetesAssn).
# # #